PT2822590T - Formulação de anticorpo de il-17 - Google Patents

Formulação de anticorpo de il-17

Info

Publication number
PT2822590T
PT2822590T PT137102141T PT13710214T PT2822590T PT 2822590 T PT2822590 T PT 2822590T PT 137102141 T PT137102141 T PT 137102141T PT 13710214 T PT13710214 T PT 13710214T PT 2822590 T PT2822590 T PT 2822590T
Authority
PT
Portugal
Prior art keywords
antibody formulation
antibody
formulation
Prior art date
Application number
PT137102141T
Other languages
English (en)
Portuguese (pt)
Inventor
John Corvari Vincent
Ann Williams Barbara
Daniel Donovan Patrick
Paul Markham Aaron
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT2822590T publication Critical patent/PT2822590T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT137102141T 2012-03-07 2013-03-01 Formulação de anticorpo de il-17 PT2822590T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261607671P 2012-03-07 2012-03-07

Publications (1)

Publication Number Publication Date
PT2822590T true PT2822590T (pt) 2016-12-15

Family

ID=47892018

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137102141T PT2822590T (pt) 2012-03-07 2013-03-01 Formulação de anticorpo de il-17

Country Status (34)

Country Link
US (3) US9376491B2 (enExample)
EP (2) EP2822590B1 (enExample)
JP (1) JP6117252B2 (enExample)
KR (1) KR101653082B1 (enExample)
CN (1) CN104159612B (enExample)
AU (1) AU2013230490B2 (enExample)
BR (1) BR112014021308B1 (enExample)
CA (1) CA2866128C (enExample)
CL (1) CL2014002204A1 (enExample)
CY (1) CY1118393T1 (enExample)
DK (1) DK2822590T3 (enExample)
EA (1) EA030742B1 (enExample)
EC (1) ECSP14017562A (enExample)
ES (1) ES2610707T3 (enExample)
HR (1) HRP20161604T1 (enExample)
HU (1) HUE031290T2 (enExample)
IL (1) IL234053B (enExample)
LT (1) LT2822590T (enExample)
MA (1) MA37317B1 (enExample)
ME (1) ME02565B (enExample)
MX (1) MX362191B (enExample)
MY (1) MY167233A (enExample)
NZ (1) NZ627648A (enExample)
PE (1) PE20142275A1 (enExample)
PH (1) PH12014501985B1 (enExample)
PL (1) PL2822590T3 (enExample)
PT (1) PT2822590T (enExample)
RS (1) RS55417B1 (enExample)
SG (1) SG11201404491XA (enExample)
SI (1) SI2822590T1 (enExample)
TN (1) TN2014000341A1 (enExample)
UA (1) UA114620C2 (enExample)
WO (1) WO2013134052A1 (enExample)
ZA (1) ZA201405654B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
WO2019027828A1 (en) 2017-08-04 2019-02-07 Eli Lilly And Company DOSAGE SCHEME OF ANTI-IL-17 ANTIBODIES
EP3672988A1 (en) * 2017-08-23 2020-07-01 Eli Lilly and Company Treatment of genital psoriasis
MX2017016884A (es) * 2017-12-19 2019-06-20 Probiomed S A De C V Formulacion farmaceutica estable de una proteina anti-tnfa.
JP2022513693A (ja) * 2018-11-29 2022-02-09 ハーバー・バイオメド・セラピューティクス・リミテッド 抗pd-l1抗体製剤
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
CN112915201B (zh) * 2019-12-06 2023-06-27 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
US20240052026A1 (en) * 2020-12-22 2024-02-15 Bio-Thera Solutions, Ltd. Stable antibody formulation, preparation method therefor, and applications thereof
CN119147687B (zh) * 2024-11-11 2025-03-14 智翔(上海)医药科技有限公司 用于抗白介素17a抗体质量检测的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1963368T6 (pl) * 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
WO2008068246A1 (en) * 2006-12-05 2008-06-12 Crucell Holland B.V. Liquid anti-rabies antibody formulations
SI2523688T1 (en) * 2010-01-15 2018-03-30 Kirin-Amgen, Inc. Formulation of antibodies and therapeutic regimes

Also Published As

Publication number Publication date
UA114620C2 (uk) 2017-07-10
US9845353B2 (en) 2017-12-19
JP2015510882A (ja) 2015-04-13
IL234053B (en) 2018-06-28
LT2822590T (lt) 2017-01-25
US20150010573A1 (en) 2015-01-08
IL234053A0 (en) 2014-09-30
MY167233A (en) 2018-08-14
AU2013230490A1 (en) 2014-08-14
WO2013134052A1 (en) 2013-09-12
EA201491471A1 (ru) 2014-12-30
PL2822590T3 (pl) 2017-06-30
AU2013230490B2 (en) 2017-04-13
EP3156073A1 (en) 2017-04-19
MA37317B1 (fr) 2016-10-31
BR112014021308B1 (pt) 2022-08-30
US20160280781A1 (en) 2016-09-29
SG11201404491XA (en) 2014-09-26
CY1118393T1 (el) 2017-06-28
PH12014501985A1 (en) 2014-11-24
CL2014002204A1 (es) 2015-01-30
EP2822590A1 (en) 2015-01-14
CN104159612B (zh) 2016-03-16
HK1199844A1 (en) 2015-07-24
EA030742B1 (ru) 2018-09-28
PE20142275A1 (es) 2015-01-08
PH12014501985B1 (en) 2014-11-24
DK2822590T3 (en) 2017-01-23
SI2822590T1 (sl) 2017-01-31
KR101653082B1 (ko) 2016-08-31
KR20140120938A (ko) 2014-10-14
TN2014000341A1 (en) 2015-12-21
RS55417B1 (sr) 2017-04-28
CN104159612A (zh) 2014-11-19
ES2610707T3 (es) 2017-05-03
MX362191B (es) 2019-01-08
ECSP14017562A (es) 2015-09-30
ZA201405654B (en) 2016-05-25
US20180057584A1 (en) 2018-03-01
US9376491B2 (en) 2016-06-28
CA2866128A1 (en) 2013-09-12
MX2014010710A (es) 2015-04-14
US10472416B2 (en) 2019-11-12
HRP20161604T1 (hr) 2016-12-30
HUE031290T2 (hu) 2017-06-28
ME02565B (me) 2017-02-20
CA2866128C (en) 2017-02-28
EP2822590B1 (en) 2016-10-26
JP6117252B2 (ja) 2017-04-19
NZ627648A (en) 2016-10-28
MA37317A1 (fr) 2016-03-31
BR112014021308A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
IL235966A0 (en) Antibody formulation
PL3117837T3 (pl) Formulacje przeciwciała
IL234120B (en) A formulation containing an antibody against abeta
DK2890397T3 (da) Antiprolactinreceptor-antistofformulering
ZA201407316B (en) Anti-fgfr2 antibody
IL237287A0 (en) Antibody compositions and their uses
ZA201504564B (en) Anti her2 antibody formulation
IL234053A0 (en) Formulation of il–17 antibody
ZA201407079B (en) Cdr-modified anti-siglec-15 antibody
IL233794A0 (en) Antibody against phospholipase d4
GB201220242D0 (en) Antibody
EP2811018A4 (en) ANTI-BODY ANTI-sAPPß
GB201216749D0 (en) Antigen combinations
GB201200568D0 (en) Antigen combinations
PH32012000710S1 (en) Quadricycle